Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 14
Phase 21

Trial Status

Completed4
Terminated1

Role Distribution

Other Roles5

Activity Timeline

Clinical Trials (5)

NCT04171752Phase 1Completed
Elafibranor Pharmacokinetic Parameters in Elderly Healthy Volunteers
GeriatricsHealthy
StudydirectorStart date: 2019-11-22
NCT03985969Phase 1Completed
Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin
Drug-drug Interaction
StudydirectorStart date: 2019-09-23
NCT03844555Phase 1Completed
Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients
Kidney DiseasesPharmacokineticsRenal Impairment+1 more
StudydirectorStart date: 2019-02-28
NCT03765671Phase 1Completed
Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients
Hepatic ImpairmentLiver DiseasePharmacokinetics
StudydirectorStart date: 2018-12-12

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Publications (0)

No publications found for this investigator.

Clinical Trials (5)

Showing 5 of 5 trials

NCT04171752Phase 1StudyDirector

Elafibranor Pharmacokinetic Parameters in Elderly Healthy Volunteers

GeriatricsHealthy
Completed
NCT03985969Phase 1StudyDirector

Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin

Drug-drug Interaction
Completed
NCT03953456Phase 2StudyDirector

Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)

Non-Alcoholic Fatty Liver
Terminated
NCT03844555Phase 1StudyDirector

Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients

Kidney DiseasesPharmacokineticsRenal Impairment+1 more
Completed
NCT03765671Phase 1StudyDirector

Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients

Hepatic ImpairmentLiver DiseasePharmacokinetics
Completed

All 5 trials loaded